Compass gains on new late-stage trial data for psychedelic therapy in depression
Seeking Alpha ·
Compass Pathways ( CMPS ) added ~8% in early premarket trading on Tuesday after the U.K.-based biotech announced additional data from a second ongoing late-stage trial for its psychedelic therapy COMP360 against treatment-resistant depression. The 26-week results from the Part B portion
DYAX Investor Sentiment
Bullish (Long) 65% · Bearish (Short) 35%
361 participants
Related News
- Abacus Global Management to tokenize secondary life insurance assets
- CCHH's unit signs $50M three-year Malaysia data center services deal
- Splash Beverage Group acquires global rights to CannEpil, secures financing and 20-year license
- United Microelectronics sales beat suggests improvement in business: Wedbush
- Nvidia-backed Nscale closes $900M revolving credit facility
- Nvidia, AMD chips face further displacement in China from domestic options: survey